☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
active psoriatic arthritis
UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis
November 22, 2021
Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis
November 2, 2021
AbbVie-Skyrizi (risankizumab) Receives CHMP's Positive Opinion for the Treatment of Adults with Active Psoriatic Arthritis in the...
October 18, 2021
Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis
March 17, 2021
AbbVie Reports Results of Skyrizi (Risankizumab) in P-III Studies for Active Psoriatic Arthritis
January 6, 2021
Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthriti...
September 11, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.